Читать книгу Drug Transporters - Группа авторов - Страница 108

The impact of SLC22A1/OCT1 and SLC47A1/MATE1 polymorphisms on clinical response to metformin in patients with castration‐resistant prostate cancer was evaluated [123]. Patients (n = 36) received metformin until disease progression or toxicity (diarrhea, bloating, anorexia, nausea, fatigue). Disease progression was greater in the C/C genotype for SLC22A1 (80%, rs622342) vs. carriers of the A allele (28.6%) and for carriers of the SLC47A1 A allele (44%, rs2289669) as compared with G/G wild‐type genotype (12.5%). Patients who were carriers of at least one A allele for SLC22A1 (41.9%) versus C/C genotype exhibited increased metformin levels. The authors concluded that polymorphisms in drug transporters may be viable biomarkers to predict progression and toxicity to metformin in clinical studies for castration‐resistant prostate cancer.